SYNCRIP and ovarian cancer: Utilizing a lentiviral overexpression system, we demonstrated that elevated levels of SYNCRIP or SNU13 increased the resistance of ovarian cancer cells to cisplatin (Fig. 6A; Supplementary Fig. 7A, B).